RT @drdavidliew: Should we in rheumatology be the ones leading the trials using our drugs with checkpoint inhibitors? C
Tweet Content
Should we in rheumatology be the ones leading the trials using our drugs with checkpoint inhibitors?
Can we learn lessons about collaborative work from @rheum_covid?
Provoking questions for the new challenges in treatment of irAEs! https://t.co/chl8TeOoMy
Show on Archive Page
On
Display in Search Results
On